{"id":1811,"date":"2017-01-24T12:26:34","date_gmt":"2017-01-24T12:26:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1811"},"modified":"2021-07-24T12:56:38","modified_gmt":"2021-07-24T07:26:38","slug":"notizia-23","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-23","title":{"rendered":"U.K. weighs drug rationing;  Applying Digital; FDA slaps Florida"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f1d1aa1f8f2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f1d1aa1f8f2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\/#UK_weighs_drug_rationing_as_NHS_Englands_budget_tightens_report\" >U.K. weighs drug rationing as NHS England&#8217;s budget tightens: report<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\/#Applying_Digital_Technologies_to_Profit_from_Change_in_the_Pharma_Industry\" >Applying Digital Technologies to Profit from Change in the Pharma Industry<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\/#Drugmakers_%E2%80%98hijacked_the_FDAs_orphan_system_to_score_premium_pricing_on_mass-market_meds\" >Drugmakers &#8216;hijacked&#8217; the FDA&#8217;s orphan system to score premium pricing on mass-market meds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\/#FDA_slaps_Florida_blow-seal-fill_facility_with_warning_letter\" >FDA slaps Florida blow-seal-fill facility with warning letter<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"UK_weighs_drug_rationing_as_NHS_Englands_budget_tightens_report\"><\/span>U.K. weighs drug rationing as NHS England&#8217;s budget tightens: report<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing costly drugs. Among them are medicines from Johnson &amp; Johnson, Merck and Roche. Beginning in April, cancer patients and others could have to line up for medicines that cost NHS England more than \u00a320 million per year, The Times reported. That\u2019s even after those meds have been deemed cost-effective by the National Institute for Health and Care Excellence (NICE). The move comes at a troublesome time at NHS, as its chief executive, Simon Stevens, said publicly this month that Prime Minister Theresa May was &#8220;stretching the truth&#8221; about the agency&#8217;s budget. He said NHS received &#8220;less than we asked for&#8221; from the British government.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Applying_Digital_Technologies_to_Profit_from_Change_in_the_Pharma_Industry\"><\/span>Applying Digital Technologies to Profit from Change in the Pharma Industry<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Pharmaceutical companies are increasingly challenged to keep pace with the evolving demands of patients, physicians and payers. Patients are increasingly seeking higher levels of involvement and understanding of their own treatment plans. In fact, a recent survey found that more than 85% of patients are confident in their ability to take responsibility for their health and knew where to access online resources to do so. Much of this information is sought after via mobile devices: over 60% of smartphone users use their mobile devices to search for information regarding a health condition. Furthermore, patients are increasingly favoring third party sites where they can obtain syndicated information on health conditions and related treatments.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Drugmakers_%E2%80%98hijacked_the_FDAs_orphan_system_to_score_premium_pricing_on_mass-market_meds\"><\/span>Drugmakers &#8216;hijacked&#8217; the FDA&#8217;s orphan system to score premium pricing on mass-market meds<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">There\u2019s no denying that financial incentives for orphan drug development saved hundreds of thousands of lives. But they\u2019ve also helped mass-market drug makers rack up millions in incentives, tax breaks and patent-protected profit. According to a report, About one-third of the orphan drug approvals since the program began have been for repurposed, large-market products or drugs with multiple orphan green lights. Best-sellers such as Crestor from AstraZeneca, Abilify from Otsuka, Herceptin from Roche and Humira from AbbVie fall into the category of big sellers whose makers snagged millions in government incentives\u2014not to mention seven years of exclusive rights on the market\u2014when they resubmitted their therapies as treatments for smaller populations. Others, such as Allergan blockbuster Botox, started out as small-market meds and proceeded to collect multiple orphan approvals.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"FDA_slaps_Florida_blow-seal-fill_facility_with_warning_letter\"><\/span>FDA slaps Florida blow-seal-fill facility with warning letter<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The FDA has come down on an aseptic blow-fill-seal pharma manufacturing operating in Florida that the agency says has widespread issues with microbiological contamination. The FDA posted a warning letter that was issued last month to Horizon Pharmaceuticals following an inspection that dates back to the fall of 2015. The FDA said that when it inspected the company\u2019s facility in Riviera Beach, Florida, it \u201cfound multiple deficient practices at (the) facility that pose a significant microbiological contamination risk.\u201d Among those was its cleaning and disinfection program, which it said didn\u2019t use a sporicidal agent. The inspectors discovered the facility had shipped three lots of an ophthalmic drug even though some bottles which were tested were contaminated with Bacillus mycoides, which is a spore-forming microbe.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>U.K. weighs drug rationing as NHS England&#8217;s budget tightens: report Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing costly drugs. Among them are medicines from Johnson &amp; Johnson, Merck and Roche. Beginning in April, cancer patients and others could [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,17421,420,712,755,17422,595],"industry":[17225],"therapeutic_areas":[17244,17234],"class_list":["post-1811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-brainstorm-cell-therapeutics","tag-news","tag-pharma-industry","tag-regulatory","tag-trivitron-healthcare","tag-usfda","industry-pharmaceutical","therapeutic_areas-ophthalmology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NHS&#039;s budget; Pharma digitalisation; FDA&#039;s warning; FDA&#039;s orphan system<\/title>\n<meta name=\"description\" content=\"Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHS&#039;s budget; Pharma digitalisation; FDA&#039;s warning; FDA&#039;s orphan system\" \/>\n<meta property=\"og:description\" content=\"Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-23\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-24T12:26:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"681\" \/>\n\t<meta property=\"og:image:height\" content=\"243\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHS's budget; Pharma digitalisation; FDA's warning; FDA's orphan system","description":"Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-23","og_locale":"en_US","og_type":"article","og_title":"NHS's budget; Pharma digitalisation; FDA's warning; FDA's orphan system","og_description":"Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-23","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-01-24T12:26:34+00:00","article_modified_time":"2021-07-24T07:26:38+00:00","og_image":[{"width":681,"height":243,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-23","url":"https:\/\/www.delveinsight.com\/blog\/notizia-23","name":"NHS's budget; Pharma digitalisation; FDA's warning; FDA's orphan system","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-23#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-23#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","datePublished":"2017-01-24T12:26:34+00:00","dateModified":"2021-07-24T07:26:38+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Patients in the U.K. face yet another barrier to access as a tough budget situation has forced the country\u2019s healthcare system to consider rationing...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-23"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-23#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02.jpg","width":681,"height":243},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/04164451\/news_02-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Brainstorm Cell Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Regulatory<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Trivitron Healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USFDA<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Brainstorm Cell Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Regulatory<\/span>","<span class=\"advgb-post-tax-term\">Trivitron Healthcare<\/span>","<span class=\"advgb-post-tax-term\">USFDA<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 24, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 24, 2017 12:26 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1811"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1811\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1247"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1811"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1811"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}